Código QR (código de barras bidimensional)

Trastuzumab Resistance, a Potential Roadblock for Most Successful Therapy of Breast Cancer—An Updated Review of Underlying Mechanisms, Clinical Trials and Patents to Evade the Resistance

Trastuzumab is the first humanised monoclonal antibody (Mab) developed for breast cancer (BC) therapy. The high affinity of Trastuzumab Fab-domain binding to the human epidermal growth factor receptor 2 (HER2) receptor, with a K<sub>d</sub> value of <1 nM, is also accompanied by Fc domain interactio...

תיאור מלא

שמור ב:
Principais autores: Gul Hasan, Soudipta Pramanik, Sandhya Singh, Pravin Gurav, Sudha Madhavi Penumaka, Sudheer Kumar, Debabrata Mandal
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI AG 2026-04-01
סדרה:Pharmaceutics
נושאים:
trastuzumab resistance
HER2 receptor
PI3K/AKT/mTOR pathway
Mucin1
combination therapy
patents & clinical trials
גישה מקוונת:https://www.mdpi.com/1999-4923/18/5/514
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים